Firefly Neuroscience, Inc., and its wholly-owned subsidiary, Firefly Neuroscience Ltd., are engaged in the development, marketing and distribution of medical devices and technologies to enable high-resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain. Firefly Neuroscience Ltd., originally established in 2006 under the laws of the State of Israel and started operations as a development company, launched its US marketing and distribution activities in May 2014 through Elminda 2022 Inc.
